Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

CAR-T cell therapy in oncology

By Brian Huber and Tamie Joeckel

- PMLiVE

AbbVie to acquire DJS Antibodies in $255m cash deal

The agreement includes DJS-002, an experimental drug for idiopathic pulmonary fibrosis

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

- PMLiVE

Merck’s Prevymis shows promise in phase 3 cytomegalovirus disease prevention trial

The drug demonstrated non-inferior efficacy compared to standard of care valganciclovir

- PMLiVE

NHS to roll out brain laser therapy for epilepsy patients

There are around 600,000 people living with epilepsy across the UK

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

- PMLiVE

Innovative Trials featuring in a Clinical Trials Arena article

Leanne Keem, Head of Operations and Client Relationship at Innovative Trials, featured in a recent article.

Innovative Trials

- PMLiVE

Closing The Gaps in Patient-Centricity in Cancer Care

Highlights from the Medscape Education full panel discussion during this year's #ESMO22.

Medscape Education

Full Panel Discussion: Closing The Gaps In Patient-Centricity

On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

Medscape Education

- PMLiVE

A day late and a dollar short

By Rohit Khanna

EVOKE STRENGTHENS LEADERSHIP TEAM IN EUROPE TO DELIVER MORE INTEGRATED CLIENT SOLUTIONS

*Corrina Safeio, promoted to Group Managing Director taking on responsibility for Evoke London and Evoke Mind+Matter *Lee Wales, promoted to Deputy Managing Director at Evoke Mind+Matter UK *Holly Ford, promoted...

Inizio

- PMLiVE

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links